A landmark study presented at the ECTRIMS 2025 conference in Barcelona, Spain, provides new insights into how menopause influences the symptoms and comorbidities of multiple sclerosis (MS) in women. The research highlights that hormonal changes during menopause can alter the initial symptoms experienced by women with MS and impact the health complications they face.
This study is particularly significant for companies like Clene Inc. (NASDAQ: CLNN), which focuses on developing novel treatments for MS and other neurodegenerative diseases. Understanding the role of hormonal shifts could lead to more targeted therapies that address the specific needs of women with MS, especially as they transition through menopause.
The findings underscore the importance of considering hormonal factors in MS research and treatment. For the estimated 2.8 million people worldwide living with MS, of whom approximately 75% are women, these insights could pave the way for personalized medicine approaches. The study suggests that menopause may exacerbate certain MS symptoms, such as fatigue, cognitive decline, and mobility issues, while also influencing the development of comorbidities like depression and osteoporosis.
Researchers analyzed data from a large cohort of women with MS, tracking changes in symptom severity and comorbidity incidence before, during, and after menopause. The results indicate that the decline in estrogen and progesterone levels during menopause can modulate immune responses and neuroprotection, potentially altering the course of MS. This hormonal shift may also affect the efficacy of existing MS treatments, highlighting the need for clinical trials that include menopausal women.
The implications of this study extend beyond MS, as it contributes to a growing body of evidence on the role of sex hormones in neurodegenerative diseases. By recognizing the impact of menopause on MS, healthcare providers can better tailor treatment plans and offer supportive care to improve quality of life for women with MS.
For investors and stakeholders, this research emphasizes the potential for developing hormone-based therapies or adjusting existing treatments to account for menopausal changes. Clene Inc., with its focus on innovative therapies, may benefit from incorporating these findings into its research and development pipeline.
As the scientific community continues to explore the intersection of hormones and neurodegeneration, this study marks a crucial step toward understanding and managing MS in women. The full details of the research are available through the Clene Inc. newsroom and the ECTRIMS conference proceedings.
